Overview

Low Dose of Metronomic Cyclophosphamide and Capecitabine in Pretreated HER2-negative Metastatic Breast Cancer

Status:
Unknown status
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the role of low dose metronomic cyclophosphamide and capecitabine in pretreated metastatic breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Fudan University
Treatments:
Capecitabine
Cyclophosphamide